Targeted therapies in thyroid cancer: an extensive review of the literature.

INTRODUCTION: Patients with progressive, metastatic, RAI-refractory differentiated thyroid cancer (DTC), as well as patients with advanced medullary (MTC) and anaplastic thyroid cancer represent a cohort for which therapeutic options are limited. The recent discoveries in the molecular mechanisms implicated in TC have provided insight of the pathogenesis and progression of disease. In that respect, targeted therapies have emerged as a promising alternative for the treatment of those patients. Areas covered: Tyrosine Kinase Inhibitors (TKIs) have been studied extensively in TC: sorafenib and lenvatinib have been approved by the FDA for the treatment of metastatic, RAI-refractory DTC, while vandetanib and cabozantinib are FDA approved for use in advanced MTC. Moreover, several additional TKIs, multi-targeted or specific, are currently under investigation in TC. The current manuscript provides an extensive review of the literature regarding targeted therapies in TC including the rationale behind their use, the clinical trials and an expert opinion on their use. Literature in English appearing at PubMed was thoroughly reviewed, especially manuscripts of the last 5 years. Expert commentary: Patients with advanced, progressive, metastatic TC should be evaluated for enrollment in a clinical trial or should be placed on treatment with one of the FDA- and EMA- approved agents.

A 29-year-old man with an unusual cause of an abscess.

A 29-year-old man with no medical history presented with a left scalp abscess and left temporal oedema. He was initially started on treatment for community acquired Methicillin-resistant Staphylococcus aureus with sulfamethoxazole and trimethoprim. Over the next 2 weeks, his swelling improved; however, he continued to have localised swelling and drainage from the area. Eventually, larvae of a botfly were removed from his scalp, and his symptoms resolved.